Clinical and histopathological risk associated with brain metastasis-free survival in breast cancer.

e11551 Background: Brain metastases (BM) are usually a late event process in metastatic breast cancer. Brain metastases free survival (BMFS) is defined as the interval from diagnosis of extracranial breast cancer metastases until diagnosis of brain metastases. Methods: We aimed to determine clinical and histopathological risk factors associated with early development of 65 breast cancer patients who developed BM during follow-up between 2004 and 2014 in a single institution. Results: 47 patients had locally-advanced disease at the time of diagnosis, and 11 had already metastatic disease. None of early breast cancer patients had BM as the first site of metastases (0/25), however those with locally advanced (15/25) or stage-IV (10/25) at diagnosis presented with BM as the first site of metastasis. The median BMFS was 40 months (7-294m); even if the first relapse was central nervous system, it was 30m versus 81m if brain was not the first metastatic site (p = 0,000, HR 3,34). The estrogen receptor negative s...